Abstract 482P
Background
Identification of EGFRm in early-stage NSCLC determines the prognosis and is predictive of response to targeted therapy. EARLY-EGFR (NCT04742192) is the first real-world study describing the prevalence of EGFRm and treatment patterns in pts with early-stage NSCLC.
Methods
This prospective, non-interventional study consecutively enrolled pts with surgically-resected stage IA-IIIB non-squamous NSCLC from 14 countries across Asia, Latin America and the Middle East and Africa. [EJ1] [NP[2] Here, we describe the prevalence of EGFRm and its subtypes, clinico-demographics and treatment patterns for patients enrolled from Aug 2021 to Sep 2022 in the Singapore cohort.
Results
A total of 71 pts were enrolled (mean±SD age 67.3±8.5 yrs); 54.9% were females and 66.2% were never smokers. Most pts had adenocarcinoma (98.6%), stage I NSCLC (73.2%), right lung tumour (64.8%), T2a/b stage (52.1%) and pN0 (81.7%). About 83% (38/46) of the cases were discussed in a multidisciplinary team (MDT) meeting (pre-operative: 55.3%, post-operative: 31.6%, both: 13.2%). The EGFRm prevalence was 63.8% (44/69). The EGFR subtypes included exon-19 del (29, 65.9%), exon 21-L858R (11, 25.0%) and uncommon mutations (4, 9.1%). Of 15 pts with PD-L1 test report, 8 had PD-L1>1%; 5 of them had EGFRm. Overall, 76.1% (54/71) underwent only surgical resection without any adjuvant treatment. Adjuvant therapy was planned in 16 pts (22.5%): IA (1), IB (04), IIA (2), IIB (5), IIIA (3), IIIB (1). Of the 48 pts with stage IB-IIIB, 15 (31.3%) were prescribed systemic therapy (ST); targeted therapy was planned in 2 pts. No pt received neo-adjuvant ST. Table: 482P
Prevalence of EGFRm
Characteristics | N=71, n (%) | Mutation rate | |||
EGFRm (N=44), n | EGFR wild type (N=25), n | Mutation rate (%) | |||
Age (yrs) | <60 | 14 (19.7) | 10 | 3 | 76.9 |
60-80 | 54 (76.1) | 31 | 22 | 58.5 | |
>80 | 3 (4.2) | 3 | 0 | 100 | |
Gender | Female | 39 (54.9) | 25 | 13 | 65.8 |
Male | 32 (45.1) | 19 | 12 | 61.3 | |
Histology | Adenocarcinoma | 70 (98.6) | 43 | 25 | 63.2 |
Others | 01 (1.4) | 1 | 0 | 100 | |
Smoking* | Current | 04 (5.6) | 2 | 1 | 66.7 |
Former | 20 (28.2) | 9 | 11 | 45.0 | |
Never | 47 (66.2) | 33 | 13 | 71.7 | |
Stage (AJCC 8th edi.) | IA | 23 (32.4) | 15 | 8 | 65.2 |
IB | 29 (40.8) | 17 | 12 | 58.6 | |
IIA | 3 (4.2) | 1 | 1 | 50.0 | |
IIB | 09 (12.7) | 5 | 3 | 62.5 | |
IIIA | 06 (8.4) | 5 | 1 | 83.3 | |
IIIB | 01 (1.4) | 1 | 0 | 100.0 |
Two pts failed EGFR test *p = 0.051: comparison between current and former vs. never smoker Unknown/missing data not included
Conclusions
Our study reports a high prevalence of EGFRm (63.8%). Of 29 and 19 pts with stage IB and II-III NSCLC, ST was planned in 4 and 9 pts, respectively, highlighting the need to comply with international guidelines. Our data calls for biomarker profiling of early-stage NSCLC to ensure appropriate management through MDT.
Clinical trial identification
NCT04742192.
Editorial acknowledgement
Medical writing support was provided by Prajakta Nachane (M. Pharm) of Fortrea Scientific Pvt Ltd funded by AstraZeneca FZ LLC in accordance with GPP 2022 guidelines.
Legal entity responsible for the study
AstraZeneca International.
Funding
AstraZeneca International.
Disclosure
P.L. Chia: Other, Personal, Advisory Board: AstraZeneca, Merck, Amgen, Pfizer, Bayer; Financial Interests, Personal, Other, Honoraria for symposium: AstraZeneca, Lung Cancer Consortium Singapore; Financial Interests, Institutional, Research Funding: AstraZeneca. J.T. Kit Chung: Financial Interests, Personal, Speaker, Consultant, Advisor, Advisory and Consultancy with AstraZeneca, BMS, MSD: AstraZeneca, BMS, MSD. A. Asmat: Financial Interests, Personal, Other, Honorarium from MSD for participation in an early stage NSCLC Expert Input Forum in August 2023: MSD. R. Huggenberger: Financial Interests, Personal, Full or part-time Employment, I am an employee of AstraZeneca: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca, Innate Pharma, Chinook Therapeutics, Adaptimmune Therapeutics, CStone Pharmaceuticals, Allogene Therapeutics, Imugene Limited, Swedish Orphan Biovitrium, Cullinan Oncology, Blueprint Medicines, GSK, Gritstone Bio, Compugen, Arcutis Biotherapeutics, Syndax Pharmaceuticals, Eli Lilly. A. Verma: Other, Personal, Full or part-time Employment: AstraZeneca. R.A. Soo: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BMS, Lily, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan, Thermo Fisher, Janssen, Merck Serono, Puma Biotech; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract